Introduction {#sec1-1}
============

Preterm labour is defined as the presence of uterine contractions of sufficient frequency and intensity to effect progressive effacement and dilatation of the cervix before term gestation (between 20 and 37 weeks).\[[@ref1]\] Preterm birth is a major contributor to perinatal mortality and morbidity, affecting around 9% of births in high income countries and an estimated 13% of births in low and middle income countries.\[[@ref2]\] If there are uterine contractions with no corresponding cervical dilatation, then it can be considered as threatened preterm labour.\[[@ref3]\] The exact mechanism of preterm labour is unknown but is believed to include multiple gestation, polyhydramnios, cervical incompetence, uterine distortion, cervical inflammation, maternal infections, fever, urinary tract infection, hormonal changes mediated by maternal or fetal stress and uteroplacental insufficiency.\[[@ref1]\] Premature contractions further result in premature labour causing fetal complications such as respiratory distress syndrome (RDS), necrotizing enterocolitis, cerebral edema and mental retardation.

Management includes rest in left lateral position, adequate hydration, antenatal corticosteroids, progesterone (orally or vaginally) and tocolytics. Prophylactic antibiotic is administered if the membrane is ruptured. Steroids are indicated in women at risk of preterm labour before 36 weeks including PPROM (Preterm premature rupture of the membranes) to accelerate lung maturity of fetus.\[[@ref4]\] Tocolytics are advised before 34 weeks of gestation. The primary purpose of tocolytic therapy is to delay delivery for 48 h to allow the maximum benefit of glucocorticoids to decrease the incidence of RDS and for *in-utero* transfer to a tertiary center. Although advances in the prevention and treatment of premature labour have improved, they have not lowered the preterm birth rate.

In Ayurveda classics, the preterm labour can be related to *Viprasava* according to *Madhukosha* commentary of *Madhava* *Nidana*\[[@ref5]\] and *Akala Prasava* according to *Arunadatta* commentary.\[[@ref6]\] Normalcy of *Shukra* (male reproductive factors), *Artava* (female reproductive factors), *Ashaya* (uterus), *Kala* (Suitable timing for conception) and diet along with life style of mother is essential for the full term delivery of matured fetus.\[[@ref7]\] Any abnormality in any of these factors may cause *Akala* *Prasava*. *Acharya Harita* opines that delivery can take place before completing full term, due to the abnormalities of *Dosha* especially propelled by *Vayu*.\[[@ref8]\] *Apana* *Vayu* is responsible for the expulsion of fetus.\[[@ref9]\] Premature labour occurs due to derangement of *Prasuti* *Maruta* *(Apana* *Vata* responsible for expulsion of foetus) due to various causes.\[[@ref10]\]

*Prachalita Garbha* and *Prasramsamana Garbha* are the terms used by ancient *Acharya* for denoting the displaced fetus from its normal position such as low lying etc. Many formulations are described for the treatment of Fetus displaced from normal position and for the prevention of *Garbhasrava* (abortion) in each month of pregnancy by *Sushruta*,\[[@ref11]\] *Vagbhata*,\[[@ref12]\] *Yogaratnakara*,\[[@ref13]\] *Harita*,\[[@ref14]\] *Bhavaprakasha*\[[@ref15]\] etc. Majority of the *Acharya* indicated the formulation for excessive pain due to *Chalita Grabha* or *Garbhasrava* as various medicated milk formulations.\[[@ref16][@ref17]\] *Ksheerapaka* has been mentioned in Ayurveda classics for treating *Prasramsamana* *Garbha* with the symptoms like *Parshva* *Prishtha* *Shoola* (pain in the flanks and low back), *Asrigdara* (bleeding per vagina) etc.\[[@ref17]\]

Case Report {#sec1-2}
===========

A 28-year-old married woman visited the Prasutitantra and Streeroga outpatient department (OPD) of Institute for Postgraduate Teaching and Research in Ayurveda, Jamnagar, on January 6, 2017 with the complaints of lower abdominal pain radiating to both thighs and low back, at 33^rd^ week of gestation. She was also complaining of reduced appetite and constipation. She was second gravida with last menstrual period on 23^rd^ May, 2016 and had estimated date of delivery on 2^nd^ March, 2017. Her antenatal period throughout was uneventful with normal ultrasonographic (USG) findings. Obstetric history revealed a previous normal delivery of a female child 5 years back with no history of abortion. Hematological, biochemical and microbiological investigations were found to be within normal limit. On examination, the general condition of the patient appeared healthy. Blood pressure (BP) was 110/80 mmHg and pulse was 70 bpm. No pallor and edema were present. Per-abdomen examination revealed longitudinal lie with cephalic presentation and fundal height corresponding to 32 weeks of pregnancy. Fetal head was found to be engaged. Mild uterine contractions lasting for 10--15 s in every 30--45 min associated with severe pain was noted. Fetal heart rate was found to be 138 bpm. Per-vaginal examination was withheld with the fear of inducing further uterine contraction.

Considering the premature contractions, she was advised admission in the Prasutitantra and Streeroga ward in inpatient department. She was advised complete bed rest with foot end elevation and light diet. Isoxsuprine hydrochloride injection 5 mg intramuscularly 6 hourly for 1 day (total 4 doses) was given. Later on, half tablet of Tidilan Retard (Isoxsuprine 40 mg) was given orally twice daily after food. Routine blood and urine investigations were carried out which were in normal range. For 2 days, abdominal pain was absent and uterus was relaxed. Vitals were normal. Fetal heart rate and fetal movements were also regular.

On the 3^rd^ day (January 8, 2017), the patient again developed lower abdominal pain and low backache. Uterine contractions lasting 10--20 s in every 30 min were present. Foetal heart sound (FHS) was 130 bpm and BP was 100/70 mm of Hg. She was given betamethasone 1 ampule IM 2 doses (12 h apart). USG showed adequate amniotic fluid index and normal fetus with engaged head. Per-vaginal examination revealed multiparous os with no effacement. Isoxsuprine tablet 20 mg (half tablet of Tidilan Retard) was repeated 6^th^ hourly orally.

On the next day (9^th^ January, 2017), the patient experienced nausea and vomiting. Appetite and sleep were found to be reduced due to the pain. The vitals and FHS were monitored 2 hourly and were found to be normal. The next day (10^th^ January, 2017) evening, again, the patient complained of severe abdominal pain and low backache. Uterine contractions were felt per abdomen lasting 15--25 s at every 20--30 min. FHS was found to be normal. On per-vaginal examination cervical dilatation was found to be 1 cm with no effacement.

Isoxsuprine tablets were discontinued and *Shatavaryadi* *Ksheerapaka* *Basti* was planned. *Ksheerapaka* consists of mainly three ingredients, i.e., *Shatavari* (*Asparagus racemosus* Willd.), *Bala* (*Sida cordifolia* Linn.) and *Arjuna* (*Terminalia arjuna* Roxb.) taken in equal amounts as shown in [Table 1](#T1){ref-type="table"}. Fine powder of *Shatavari*, *Bala* and *Arjuna* in an equal quantity of 10 g each (total 30 g) was boiled with 15 parts of milk (450 ml) and 15 parts of water (450 ml) until only milk part remains. The above procedure was carried out on mild heat. Thus, obtained *Ksheerapaka* was filtered and used for the *Basti* procedure.\[[@ref18]\] *Shatavaryadi* *Ksheerapaka* *Basti* 450 ml was administered through rectal route very slowly in the left lateral position at 5.30 pm on 10^th^ January, 2017. After evacuation of *Basti*, the patient got relief from the abdominal pain within 3--4 h. *Ksheerapaka* *Basti* was continued for 1 more day (January 11, 2017, at 7.00 am) and the patient got complete relief with no further uterine contractions or backache. She was under observation for 1 more day and was discharged on January 13, 2017. She was advised to take *Shatavaryadi* *Ksheerapaka* 90 ml orally twice daily empty stomach for a week. The patient was advised to report OPD weekly for regular antenatal checkup. The patient had continued the pregnancy till term and delivered a healthy full-term male baby of 2.7 kg on February 15, 2017 (period of gestation -- 38 weeks 2 days).

###### 

Ingredients of *Shatavaryadi Ksheerapaka Basti*
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Procedure of *Basti* {#sec2-1}
--------------------

Freshly prepared lukewarm *Shatavaryadi* *Ksheerapaka* *Basti* was administered to the patient lying in the left lateral position. First, the Enema can was attached with the tube along with nozzle having regulator for controlling the flow of the contents of *Basti*, i.e., medicated milk. The nozzle was then attached with rubber catheter no. 8 and used for administration of *Basti*. After that, *Basti* material was taken in the enema can. Anal orifice and tip of the catheter were lubricated with the *Bala Taila* (medicated oil) and air was removed from tube, nozzle and the rubber catheter. Then, the flow of *Basti* material was adjusted with the help of the regulator in the nozzle, i.e., approximately 100--120 drops/min (approximately 8--10 ml/min). After that, the tip of catheter was inserted into anal canal of the patient steadily and slowly following the curve of the vertebral column until it reached inside up to 3--4 inches. The patient was encouraged for deep breathing. Approximately 50--55 min were taken for the completion of procedure. After administration, the patient was asked to lie in supine position and rest on the table till she feels the urge for defecation. *Basti* was evacuated within 5--10 min on both days. Pre operative procedures such as *Abhyanga* (body massage) and *Swedana* (fomentation) were withheld. The posology details are mentioned in [Table 2](#T2){ref-type="table"}.

###### 

Posology of *Shatavaryadi Ksheerapaka Basti*
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Discussion {#sec1-3}
==========

Isoxsuprine hydrochloride is a beta-sympathomimetic drug. It stimulates b~2~-receptors in the uterine muscle, activating adenyl cyclase, increasing cAMP and thus reducing intracellular calcium. Isoxsuprine also produces peripheral vasodilation by a direct effect on vascular smooth muscle, primarily within skeletal muscle with little effect on cutaneous blood flow.\[[@ref19]\] Although to some extent isoxsuprine relaxes the premature uterine contractions, it is found that continuous use of isoxsuprine exhibits some adverse effects such as tachycardia, hypotension, hyperglycemia and irritable uterus. Although delivery may be delayed long enough for the administration of corticosteroids, this treatment does not result in improved perinatal outcome. Therefore, there is a definite need for alternative, safe and effective treatment to arrest the preterm contractions right from the beginning.

Increased premature contractions (*Avi*) are induced due to vitiation of *Vata* mainly *Apana* *Vata*. For alleviating *Vata*, the best method is *Basti*.\[[@ref20]\] *Basti* causes evacuation of stools and thereby relives premature contraction caused due to constipation. *Basti* is also indicated in the pregnant women after the completion of the 7^th^ month.\[[@ref21]\] Moreover, the drugs given in *Basti* form have specific target action and quick absorption. *Shatavaryadi* *Ksheerapaka* is planned in this case study as it shows antioxytocic effect relieving the uterine contractions. It is given in *Basti* form, as larger quantity of drug can be administered for effective action and quick absorption through this route. *Ksheera* *Basti* further normalizes *Vata* by the downward movement and relieves any sort of pain. The properties and action of the ingredients of *Shatavaryadi* *Ksheerapaka* *Basti* are shown in [Table 3](#T3){ref-type="table"}.

###### 

Properties and pharmacological action of the drugs in *Shatavaryadi Ksheerapaka*
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*Shatavari* and *Bala* possess *Rasayana* (rejuvinating), *Garbha Poshaka* (nourishing the fetus), *Balya* (strengthening) and *Pushtidayaka* (anabolic) action, which maintains and supports the pregnancy. *Vata* pacifying property of *Bala* controls the *Apana Vata* and subsides the premature contraction and pain. *Prajasthapana* (procreative) and *Ojo Vardhaka* (revitalizing) properties prevent premature labor and stabilize the *Ojas*. *Arjuna* possesses *Sandhanakara* (healing) property, which normalizes the uterine musculature and its *Shonita Prasadana* (blood purifying) property may increase the blood supply of uterus.

Many studies have proven antioxytocic effect of *Shatavari*. Alcoholic extract of *Shatavari* was found to produce a specific block of pitocin induced contraction, confirming its action as uterine sedative.\[[@ref31]\] Further, Shatavarin 1; a glycoside isolated from the roots of *Shatavari*, was found to be responsible for the competitive block of oxytocin induced contraction of rat, guinea pig and rabbits uteri, *in vitro* as well as *in* *vivo*.\[[@ref32]\] The saponin rich fraction obtained from *Shatavari* was found to inhibit oxytocin induced uterine contractions *in*-*vivo*.\[[@ref33]\]

*Bala*, *Arjuna* and *Shatavari* have antistress, adaptogenic, antioxidant, and free radical scavenging properties, which decreases cellular sensitivity to stress. They are protective against other general stressors such as oxidative stress. *Arjuna* is also capable of producing vasodilation and thus prevents the premature contractions. *Arjuna* has hypotensive and cardiotonic properties and beneficial in preterm labor caused due to hypertension.

Genital tract infections trigger the preterm labor by stimulating the prostaglandin synthesis which in turn induces preterm contractions. Methanol extract of *Shatavari* shows antibacterial activity. The anticandicidal property of *Bala*; diuretic, antibacterial and antiviral action of aqueous extract of *Arjuna* and antibacterial property of *Shatavari* all together are effective in relieving genital tract infections which is a cause for preterm labour.

As there are no substitutions available for tocolytics till date to prevent preterm labour, after the initial administration of prophylactic dose of tocolytics, the uterine premature contractions may be managed by Ayurvedic drugs. *Shatavaryadi* *Ksheerapaka* *Basti* not only may subside the premature contraction by virtue of its *Balya* (strengthening), *Brimhana* (nourishing) *Prajasthapana* (procreating), *Rasayana* (rejuvinating) etc., properties but may also improve the perinatal outcome.

Conclusion {#sec1-4}
==========

In this case study, *Shatavaryadi* *Ksheerapaka* *Basti* is found to be very efficient in preventing premature contractions when administered in 8^th^ month of pregnancy. It is given in *Basti* form as larger quantity of drug can be administered for effective action and quick absorption through this route. In severe cases of premature contractions, it is better to use *Shatavaryadi* *Ksheerapaka* *Basti* after stabilizing the patient with tocolytics initially. To scientifically validate the efficacy of *Shatavaryadi* *Ksheerapaka* *Basti* in premature contractions, further clinical studies with appropriate methodology are necessary.
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